Gepants and Ditans Hisanori Kowa 1 1Department of Neurology, National Hospital Organization Matsue Medical Center Keyword: カルシトニン遺伝子関連ペプチド , CGRP , CGRP受容体拮抗薬 , 5-HT1F作動薬 , トリプタン系薬 , calcitonin gene-related peptide , CGRP receptor antagonists , 5-HT1F receptor agonists , triptan pp.315-325
Published Date 2021/4/1
DOI https://doi.org/10.11477/mf.1416201762
  • Abstract
  • Look Inside
  • Reference


The calcitonin gene-related peptide (CGRP) has been shown to play a major role in the pathophysiology of migraine in recent years. Studies have suggested that blocking CGRP signaling is an effective preventive and therapeutic strategy in patients with migraine. Triptans, considered the mainstay of antimigraine treatment cause vasoconstriction; however, gepants and ditans (two novel classes of therapeutic agents) inhibit CGRP release but do not show a vasoconstrictor effect. Both these drugs are awaiting clinical approval in Japan as antimigraine medications that can be administered to patients with cardiovascular risk factors and to those with triptan-refractory migraine.

Copyright © 2021, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院